Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Endometrial Neoplasms 2Uterine Neoplasms 1Recurrence 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Colorectal Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

Paclitaxel 34Carboplatin 27pembrolizumab 20Bevacizumab 16Letrozole 13Megestrol Acetate 10Cisplatin 9lenvatinib 8olaparib 7dostarlimab 7Metformin 7durvalumab 6abemaciclib 6Radiotherapy 6Everolimus 6niraparib 5Specimen Handling 5Nivolumab 5Medroxyprogesterone Acetate 5Magnetic Resonance Spectroscopy 5Gemcitabine 5Fluorouracil 5Docetaxel 5Biopsy 5temsirolimus 4rucaparib 4Oxaliplatin 4Fulvestrant 4Doxorubicin 4sapanisertib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Endometrial Neoplasms × gedatolisib × Clear all
NCT03675893 2025-06-15

RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer

Dana-Farber Cancer Institute

Phase 2 Recruiting
180 enrolled
Gynecologic

Ovarian Neoplasms, Endometrial Neoplasms

NCT01420081 2019-01-08

A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer

Pfizer

Phase 2 Terminated
67 enrolled 37 charts
Gynecologic

Neoplasm Metastasis, Neoplasms, Recurrence, Uterine Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡